FDC Share Price
Sector: Biotechnology & Drugs
You have to be logged in to add this to Watchlist.
Login or Register
488.25 +4.20 (0.87%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
478.85
Today’s High
494.95
52 Week Low
375.65
52 Week High
659
488.05 +2.55 (0.53%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
478.25
Today’s High
496.2
52 Week Low
378.2
52 Week High
658.85
Key Metrics
- Market Cap (In Cr) 7904.43
- Beta 0.71
- Div. Yield (%) 1.03
- P/B 3.77
- TTM P/E 27.88
- Peg Ratio 15.78
- Sector P/E 32.87
- D/E 0.01
- Open Price 483
- Prev Close 484.05
FDC Analysis
Price Analysis
-
1 Week-2.64%
-
3 Months-8.57%
-
6 Month2.16%
-
YTD22.46%
-
1 Year18.31%
Risk Meter
- 35% Low risk
- 35% Moderate risk
- 35% Balanced Risk
- 35% High risk
- 35% Extreme risk
FDC Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 1942.94
- Selling/ General/ Admin Expenses Total
- 413.4
- Depreciation/ Amortization
- 39.92
- Other Operating Expenses Total
- 534.85
- Total Operating Expense
- 1644.32
- Operating Income
- 298.62
- Net Income Before Taxes
- 396.22
- Net Income
- 305.22
- Diluted Normalized EPS
- 18.58
- Period
- 2024
- Total Assets
- 2468.09
- Total Liabilities
- 370.92
- Total Equity
- 2097.17
- Tangible Book Valueper Share Common Eq
- 128.55
- Period
- 2024
- Cashfrom Operating Activities
- 220.77
- Cashfrom Investing Activities
- -17.08
- Cashfrom Financing Activities
- -202.16
- Net Changein Cash
- 1.53
- Period
- 2023
- Total Revenue
- 1783.75
- Selling/ General/ Admin Expenses Total
- 751.53
- Depreciation/ Amortization
- 38.94
- Other Operating Expenses Total
- 17.03
- Total Operating Expense
- 1571.72
- Operating Income
- 212.04
- Net Income Before Taxes
- 257.8
- Net Income
- 194.04
- Diluted Normalized EPS
- 11.63
- Period
- 2023
- Total Assets
- 2342.94
- Total Liabilities
- 360.89
- Total Equity
- 1982.05
- Tangible Book Valueper Share Common Eq
- 119.2
- Period
- 2023
- Cashfrom Operating Activities
- 154.91
- Cashfrom Investing Activities
- 11.13
- Cashfrom Financing Activities
- -179.95
- Net Changein Cash
- -13.84
- Period
- 2022
- Total Revenue
- 1527.92
- Selling/ General/ Admin Expenses Total
- 642.69
- Depreciation/ Amortization
- 37.3
- Other Operating Expenses Total
- 15.24
- Total Operating Expense
- 1311.53
- Operating Income
- 216.38
- Net Income Before Taxes
- 289.39
- Net Income
- 216.4
- Diluted Normalized EPS
- 12.78
- Period
- 2022
- Total Assets
- 2270.2
- Total Liabilities
- 313.41
- Total Equity
- 1956.79
- Tangible Book Valueper Share Common Eq
- 115.64
- Period
- 2022
- Cashfrom Operating Activities
- 161.65
- Cashfrom Investing Activities
- -144.57
- Cashfrom Financing Activities
- -9.84
- Net Changein Cash
- 7.29
- Period
- 2021
- Total Revenue
- 1333.2
- Selling/ General/ Admin Expenses Total
- 486.56
- Depreciation/ Amortization
- 37.81
- Other Operating Expenses Total
- 31.42
- Total Operating Expense
- 1039.09
- Operating Income
- 294.12
- Net Income Before Taxes
- 387.73
- Net Income
- 301.35
- Diluted Normalized EPS
- 17.79
- Period
- 2021
- Total Assets
- 1956.23
- Total Liabilities
- 222.1
- Total Equity
- 1734.13
- Tangible Book Valueper Share Common Eq
- 102.47
- Period
- 2021
- Cashfrom Operating Activities
- 207.08
- Cashfrom Investing Activities
- -77.15
- Cashfrom Financing Activities
- -129.35
- Net Changein Cash
- 0.55
- Period
- 2020
- Total Revenue
- 1344.19
- Selling/ General/ Admin Expenses Total
- 509.35
- Depreciation/ Amortization
- 37.46
- Other Operating Expenses Total
- 38.99
- Total Operating Expense
- 1063.77
- Operating Income
- 280.43
- Net Income Before Taxes
- 320.97
- Net Income
- 239.88
- Diluted Normalized EPS
- 13.17
- Period
- 2020
- Total Assets
- 1812.93
- Total Liabilities
- 265.5
- Total Equity
- 1547.43
- Tangible Book Valueper Share Common Eq
- 90.14
- Period
- 2020
- Cashfrom Operating Activities
- 250.38
- Cashfrom Investing Activities
- -98.35
- Cashfrom Financing Activities
- -142
- Net Changein Cash
- 9.96
- Period
- 2019
- Total Revenue
- 1090.7
- Selling/ General/ Admin Expenses Total
- 422.28
- Depreciation/ Amortization
- 33.24
- Other Operating Expenses Total
- 42.47
- Total Operating Expense
- 894.04
- Operating Income
- 196.66
- Net Income Before Taxes
- 236.64
- Net Income
- 169.79
- Diluted Normalized EPS
- 9.77
- Period
- 2019
- Total Assets
- 1639.88
- Total Liabilities
- 194.65
- Total Equity
- 1445.24
- Tangible Book Valueper Share Common Eq
- 82.5
- Period
- 2019
- Cashfrom Operating Activities
- 112.43
- Cashfrom Investing Activities
- -120.33
- Cashfrom Financing Activities
- -0.07
- Net Changein Cash
- -8.21
- Period
- 2018
- Total Revenue
- 1083.09
- Selling/ General/ Admin Expenses Total
- 403.71
- Depreciation/ Amortization
- 35.14
- Other Operating Expenses Total
- 36.92
- Total Operating Expense
- 885.19
- Operating Income
- 197.9
- Net Income Before Taxes
- 240.63
- Net Income
- 173.51
- Diluted Normalized EPS
- 9.73
- Period
- 2018
- Total Assets
- 1505.21
- Total Liabilities
- 229.1
- Total Equity
- 1276.11
- Tangible Book Valueper Share Common Eq
- 72.71
- Period
- 2018
- Cashfrom Operating Activities
- 149.84
- Cashfrom Investing Activities
- 20.11
- Cashfrom Financing Activities
- -169.43
- Net Changein Cash
- 1.02
- Period
- 2024-09-30
- Total Revenue
- 513.85
- Selling/ General/ Admin Expenses Total
- 124.95
- Depreciation/ Amortization
- 13.79
- Other Operating Expenses Total
- 135.7
- Total Operating Expense
- 457.48
- Operating Income
- 56.37
- Net Income Before Taxes
- 90
- Net Income
- 72.04
- Diluted Normalized EPS
- 4.43
- Period
- 2024-09-30
- Total Assets
- 2688.08
- Total Liabilities
- 396.35
- Total Equity
- 2291.73
- Tangible Book Valueper Share Common Eq
- 140.5
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 224.7
- Cashfrom Investing Activities
- -200
- Cashfrom Financing Activities
- -5.72
- Net Changein Cash
- 19
- Period
- 2024-06-30
- Total Revenue
- 638.27
- Selling/ General/ Admin Expenses Total
- 117.21
- Depreciation/ Amortization
- 11.02
- Other Operating Expenses Total
- 143.46
- Total Operating Expense
- 502.68
- Operating Income
- 135.59
- Net Income Before Taxes
- 162.73
- Net Income
- 119.04
- Diluted Normalized EPS
- 7.31
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 462.03
- Selling/ General/ Admin Expenses Total
- 103.24
- Depreciation/ Amortization
- 10.44
- Other Operating Expenses Total
- 149.1
- Total Operating Expense
- 416.15
- Operating Income
- 45.88
- Net Income Before Taxes
- 65.21
- Net Income
- 46.28
- Diluted Normalized EPS
- 2.84
- Period
- 2024-03-31
- Total Assets
- 2468.09
- Total Liabilities
- 370.92
- Total Equity
- 2097.17
- Tangible Book Valueper Share Common Eq
- 128.55
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 220.77
- Cashfrom Investing Activities
- -17.08
- Cashfrom Financing Activities
- -202.16
- Net Changein Cash
- 1.53
- Period
- 2023-12-31
- Total Revenue
- 458.17
- Selling/ General/ Admin Expenses Total
- 103.51
- Depreciation/ Amortization
- 9.97
- Other Operating Expenses Total
- 120.11
- Total Operating Expense
- 384.35
- Operating Income
- 73.82
- Net Income Before Taxes
- 97.55
- Net Income
- 79.23
- Diluted Normalized EPS
- 4.86
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 486.37
- Selling/ General/ Admin Expenses Total
- 100.4
- Depreciation/ Amortization
- 9.87
- Other Operating Expenses Total
- 140.17
- Total Operating Expense
- 419.82
- Operating Income
- 66.55
- Net Income Before Taxes
- 92.73
- Net Income
- 69.82
- Diluted Normalized EPS
- 4.29
- Period
- 2023-09-30
- Total Assets
- 2341.68
- Total Liabilities
- 369.18
- Total Equity
- 1972.5
- Tangible Book Valueper Share Common Eq
- 120.91
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 125.23
- Cashfrom Investing Activities
- 70.19
- Cashfrom Financing Activities
- -197.02
- Net Changein Cash
- -1.4
- Period
- 2023-06-30
- Total Revenue
- 536.38
- Selling/ General/ Admin Expenses Total
- 106.25
- Depreciation/ Amortization
- 9.63
- Other Operating Expenses Total
- 125.48
- Total Operating Expense
- 424.01
- Operating Income
- 112.37
- Net Income Before Taxes
- 140.74
- Net Income
- 109.89
- Diluted Normalized EPS
- 6.62
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 434.8
- Selling/ General/ Admin Expenses Total
- 99.21
- Depreciation/ Amortization
- 9.74
- Other Operating Expenses Total
- 125.17
- Total Operating Expense
- 388.13
- Operating Income
- 46.67
- Net Income Before Taxes
- 45.11
- Net Income
- 30.71
- Diluted Normalized EPS
- 1.86
- Period
- 2023-03-31
- Total Assets
- 2342.94
- Total Liabilities
- 360.89
- Total Equity
- 1982.05
- Tangible Book Valueper Share Common Eq
- 119.2
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 154.91
- Cashfrom Investing Activities
- 11.13
- Cashfrom Financing Activities
- -179.95
- Net Changein Cash
- -13.84
- Period
- 2022-12-31
- Total Revenue
- 409.3
- Selling/ General/ Admin Expenses Total
- 95.17
- Depreciation/ Amortization
- 9.86
- Other Operating Expenses Total
- 111.82
- Total Operating Expense
- 369.92
- Operating Income
- 39.38
- Net Income Before Taxes
- 56.59
- Net Income
- 40.75
- Diluted Normalized EPS
- 2.45
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
FDC Technical
Moving Average
SMA
- 5 Day489.05
- 10 Day498.68
- 20 Day514.99
- 50 Day535.86
- 100 Day523.91
- 300 Day485.2
FDC Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Shilpa Medicare
- 911
- -24.8
- -2.65
- 959.95
- 313.55
- 7907.66
- Procter & Gamble Health
- 5085
- -39.1
- -0.76
- 5835.95
- 4640.3
- 8441.1
- FDC
- 488.25
- 4.2
- 0.87
- 659
- 375.65
- 7949.2
- Orchid Pharma
- 1450.05
- -22.95
- -1.56
- 1591.55
- 529.95
- 7354.52
- Supriya Life Sciences
- 801.8
- 97.65
- 13.87
- 833.35
- 240.1
- 6453.11
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Shilpa Medicare
- 273.35
- 4.22
- 4.6
- 7.03
- Procter & Gamble Health
- 39.2
- 15.86
- -
- -
- FDC
- 26.55
- 3.79
- 13.98
- 15.85
- Orchid Pharma
- 75.51
- 6.25
- -2.68
- -2.4
- Supriya Life Sciences
- 44.84
- 6.81
- 25.51
- 24.71
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 06-Nov-24
- Quarterly Results & Other
- 07-Aug-24
- Quarterly Results
- 29-May-24
- Audited Results
- 07-Feb-24
- Quarterly Results
- 08-Nov-23
- Quarterly Results
- 09-Aug-23
- Quarterly Results & Buy Back of shares
- 25-May-23
- Audited Results
- 09-Feb-23
- Quarterly Results
- 14-Nov-22
- Quarterly Results
- 04-Aug-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 26-Sept-24
- 06-Sept-24
- AGM
- 23-Jul-24
- 19-Jun-24
- POM
- 27-Sept-23
- 30-Aug-23
- AGM
- 17-Jul-23
- 13-Jun-23
- POM
- -
- 09-Feb-22
- Others
- -
- 09-Aug-23
- Others
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 07-Nov-24
- 22-Nov-24
- 22-Nov-24
- 5